Literature DB >> 9112585

Zopiclone: is there any dependence and abuse potential?

M Lader1.   

Abstract

Both published and unpublished data concerning the rebound, withdrawal, dependence and abuse potential of zopiclone have been reviewed. As expected for an hypnotic drug of about 5 h elimination half-life, rebound has occasionally been detected but is substantially less frequent than with equivalent benzodiazepines. Tolerance to zopiclone does not occur regularly and cross-tolerance to the benzodiazepines may help in a regimen to withdraw from the latter drugs. Dependence on long-term use, as shown by either a characteristic withdrawal syndrome or by psychological craving, is rare considering the world-wide extent of usage. Abuse (addictive non-medical use) is documented but is also rare, in comparison with the widely abused benzodiazepines. It is concluded that zopiclone has substantial advantages over the benzodiazepines in terms of dependence and abuse potential.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9112585     DOI: 10.1007/bf03160567

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  16 in total

Review 1.  Hypnotics in the elderly. What cause for concern?

Authors:  K Morgan
Journal:  Drugs       Date:  1990-11       Impact factor: 9.546

2.  Studies on the dependence-inducing potential of zopiclone and triazolam.

Authors:  K Boissl; J F Dreyfus; M Delmotte
Journal:  Pharmacology       Date:  1983       Impact factor: 2.547

3.  Evaluation of zopiclone physical dependence liability in normal volunteers.

Authors:  P Dorian; E M Sellers; H Kaplan; C Hamilton
Journal:  Pharmacology       Date:  1983       Impact factor: 2.547

4.  Zopiclone versus triazolam in insomniac geriatric patients: a specific increase in delta sleep with zopiclone.

Authors:  J Mouret; D Ruel; F Maillard; M Bianchi
Journal:  Int Clin Psychopharmacol       Date:  1990-04       Impact factor: 1.659

5.  [Comparison of the effects of zopiclone and triazolam on the sleep of normal subjects].

Authors:  M Tiberge; U Calvet; N Khayi; C Delahaye; L Arbus
Journal:  Encephale       Date:  1988 Jul-Aug       Impact factor: 1.291

Review 6.  Rebound insomnia and newer hypnotics.

Authors:  M Lader
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  Comparison of the reinforcing properties of zopiclone and triazolam in former alcoholics.

Authors:  L P Bechelli; F Navas; S A Pierangelo
Journal:  Pharmacology       Date:  1983       Impact factor: 2.547

8.  Alleviating sleep-related discontinuance symptoms associated with benzodiazepine withdrawal: a new approach.

Authors:  C M Shapiro; J G MacFarlane; A W MacLean
Journal:  J Psychosom Res       Date:  1993       Impact factor: 3.006

Review 9.  Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic.

Authors:  K L Goa; R C Heel
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

Review 10.  Rebound insomnia: its determinants and significance.

Authors:  T Roehrs; G Vogel; T Roth
Journal:  Am J Med       Date:  1990-03-02       Impact factor: 4.965

View more
  6 in total

Review 1.  Sleep disorders in the elderly.

Authors:  R Asplund
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  Drug treatment of patients with insomnia and excessive daytime sleepiness: pharmacokinetic considerations.

Authors:  S Nishino; E Mignot
Journal:  Clin Pharmacokinet       Date:  1999-10       Impact factor: 6.447

3.  Zopiclone: is it a pharmacologic agent for abuse?

Authors:  Nevio Cimolai
Journal:  Can Fam Physician       Date:  2007-12       Impact factor: 3.275

Review 4.  A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience.

Authors:  G Hajak
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.228

5.  Residual effects of zopiclone 7.5 mg on highway driving performance in insomnia patients and healthy controls: a placebo controlled crossover study.

Authors:  T R M Leufkens; J G Ramaekers; A W de Weerd; W J Riedel; A Vermeeren
Journal:  Psychopharmacology (Berl)       Date:  2014-01-24       Impact factor: 4.530

6.  Maternal Characteristics of Women Exposed to Hypnotic Benzodiazepine Receptor Agonist during Pregnancy.

Authors:  Bjarke Askaa; Espen Jimenez-Solem; Henrik Enghusen Poulsen; Jon Traerup Andersen
Journal:  Obstet Gynecol Int       Date:  2014-04-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.